Category Archive: Finance
The Central Problem With Central Banks: They Become The Greater Fools/Bag-Holders
The central problem with central banks is their mandate now includes propping up all asset markets globally. Back in the good old days before the Global Financial Meltdown of 2008-09, central bankers reckoned they could control the “animal spirits” released when the risk-on herd destabilized into a chaotic risk-off stampede. As former Federal Reserve chairman Alan […]
Goldman Fears Crude Oil’s Self-Defeating Rally
Market rebalancing derailed by price rally… The oil market rebalancing has started: weak prices in 1Q15 pushed producers to cut capex while supporting demand. This led to a recovery in prices further fueled by relief that US crude stocks would not breach capacity, strong demand and rising Middle East tensions. The rise in prices was further supported […]
Magnitude Of Falsity Is Enormous
Podcast: Play in new window | Play in new window (Duration: 13:16 — 6.1MB) DOW – 36 = 18,068 SPX – 6 = 2099 NAS – 17 = 4976 10 YR YLD – .03 = 2.25% OIL + 1.50 = 60.75 GOLD + 9.50 = 1194.00 SILV + .21 = 16.58 The Treasury market continued to sell-off this morning, pushing […]
J. C. Penney’s Recovery Is Moving Way Too Slowly
(Photo Credit: Mike Mozart) The department stores have gone through a few rough quarters. That hasn’t made the road to recovery any easier for the struggling J. C. Penney (JCP). J. C. Penney hasn’t reported a profitable 3 month period since the fourth quarter of 2012. In February J. C. Penney reported a break-even quarter, it’s […]
Afternoon Surge Claws Back Morning Losses
It was looking ugly for indices at the open, but by the close of business much of the day’s declines had been reclaimed. For the S&P, the break of the rising trendline (and 50-day MA) was looking all but certain when sellers hit the index hard in pre-market trading, but Tuesday’s finish does give bulls […]
E Orexigen Keeps Getting Slammed On Negative News
Shares of Orexigen Therapeutics (OREX) fell 13% in today’s trading session after the company reported that its health-benefit study had to end early. This study was known as the Light study, which enrolled approximately 9,000 patients to prove that taking Contrave did not increase cardiovascular risks for patients. Results from the trial were released early […]
What Dr. Strangelove Can Teach Us About Market Corrections
The full title of the classic 1964 movie is “Dr. Strangelove, Or: How I Learned to Stop Worrying and Love the Bomb”. Income focused stock market investors need to follow the advice of Dr. Strangelove and get ready to “love the correction” that many news hosts and experts are forecasting for the stock market. Financial […]
EC The Best Approach To Adjustable Retirement Withdrawals
A great deal of recent research has focused on strategies that adjust withdrawals in retirement depending on investment experience. But such strategies disrupt retirement plans by causing withdrawals to vary a lot from year to year. I’ll examine the prominent approaches for determining what will work best for clients. A simple example of an adjustable […]
Gold Daily And Silver Weekly Charts – Coiling Like A Snake – Whip It Good
When a problem comes along You must whip it When something’s goin’ wrong You must whip it Devo – Whip It The metals continue coiling as gold is held around the 1200 level and silver between 16 and 17. The ‘delivery action’ is in silver this month, and the relative scarcity of deliverable warehouse metal at […]
E FDA Panel Backs Orkambi For Cystic Fibrosis Patients
Shares of Vertex Pharmaceuticals (VRTX) are up 7% after a panel of Federal Health advisers agreed that Orkambi should be approved for Cystic Fibrosis patients. The panel voted 12-1 for approval even though the panel had some doubts about whether or not Orkambi showed a huge statistical improvement in lung function or not. This new […]
